Roche confirmed it is halting development of emugrobart after a key study failed to show consistent improvements in muscle growth and motor function, notifying European patient communities. Separately, Genentech elected to stop a late‑stage RIPK1/RIPK1‑pathway program after interim analyses indicated the asset was unlikely to meet primary endpoints. Both decisions reflect near‑term clinical readouts that failed to deliver robust efficacy in rare neuromuscular indications and raise questions about mechanism translation from preclinical models to patients. For readers: spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD) require durable motor‑function gains—endpoints that are historically hard to shift. The program terminations will free resources but also leave gaps in therapeutic options and pipeline diversity for companies targeting muscle preservation. Investors and program teams will likely re‑evaluate biomarker strategies and patient selection to improve future trial signal detection.